| Cat.No. | Name | Information |
|---|---|---|
| M24834 | Tislelizumab | Tislelizumab, a monoclonal antibody with high binding affinity to the PD-1 receptor, minimizes Fcγ receptor binding on macrophages, thereby abrogating antibody-dependent phagocytosis, a mechanism of T cell clearance and potential resistance to anti-PD-1 therapy. Tislelizumab can be used for the research of advanced squamous non-small-cell lung cancer. |
| M24734 | Risankizumab | Risankizumab (BI 655066) is a humanised IgG monoclonal antibody, targeting IL-23 p19 subunit (Kd <10 pM) and inhibiting IL-17 production induced by human IL-23 in mouse splenocytes (IC50 = 2 pM). Risankizumab can be used to research immunological and inflammatory disorders such as psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis and erythrodermic psoriasis. |
| M24701 | Zolbetuximab | Zolbetuximab (IMAB362) is a monoclonal antibody targeting Claudin-18.2. Zolbetuximab mediates specific killing of Claudin-18.2-positive cells through immune effector mechanisms. Zolbetuximab can be used for the research of gastrointestinal adenocarcinomas and pancreatic tumors. |
| M24614 | Tildrakizumab | Tildrakizumab (SCH 900222) is a humanized anti-IL-23 (p19 subunit) monoclonal antibody. IL-23 is a critical cytokine to maintain the Th17 cell phenotype. Tildrakizumab has high-affinity for single-chain IL-23 (Kd: 136 pM). Tildrakizumab is effective against moderate to severe plaque psoriasis. |
| M24605 | Concizumab | Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that binds to the Kunitz-type protease inhibitor (KPI) 2 structural domain of TFPI, thereby blocking the interaction of this structural domain with the FXa active site. Concizumab can be used in the study of haemophilia. |
| M24594 | Lecanemab | Lecanemab (BAN-2401) is an IgG1 anti-soluble aggregated amyloid beta (Aβ) monoclonal antibody. Lecanemab shows activity across oligomers, protofibrils and insoluble fibrils. Lecanemab can be used for the research of Alzheimer's Disease. |
| M21383 | Ravulizumab | Ravulizumab (ALXN1210) is a humanized monoclonal antibody that binds with high affinity to complement protein C5 and inhibits terminal complement activation, is being evaluated as an investigational approach in COVID-19-associated severe pneumonia, acute lung injury and acute respiratory distress syndrome. |
| M11172 | Reslizumab | Reslizumab (Sch 55700) is a humanized monoclonal antibody targeting human interleukin 5 (IL-5) for the study of eosinophilic asthma. Reslizumab effectively blocks il-5 function. Reslizumab inhibited IL-5-dependent cell proliferation with an IC50 of about 91.1 pM. |
| M10603 | Anti-human CD28 mAb | CD28 molecule exists on the surface of most T cells and is considered to be a specific surface molecule of T cells. The responsiveness of T cells to antigens is mainly mediated by the CD3/TCR complex, but it also depends on the cooperation of other molecules on the surface of T cells. |
| M10111 | Anti-human CD3 mAb | CD3 is an important marker of T cells, it is composed of five polypeptide chains: γ, δ, ε, ζ, and η. |
| M9416 | Durvalumab | Durvalumab (MEDI 4736) is an humanized anti-PD-L1 monoclonal antibody, it completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively. Durvalumab was inactive against the mPD-L1. |
| M9236 | Ranibizumab | Ranibizumab is a monoclonal antibody that inhibits angiogenesis by inhibiting Vascular endothelial growth factor A. |
| M8984 | Denosumab | Denosumab is designed to target RANKL (RANK ligand), a protein that acts as the primary signal to promote bone removal/resorption. |
| M8941 | GDC-0853 (Fenebrutinib) | GDC-0853 (Fenebrutinib) is a potent, selective and non-covalent bruton tyrosine kinase (Btk) inhibitor with a Ki value of 0.91 nM against BRK. |
| M6222 | Adalimumab | Adalimumab is the first fully human, recombinant IgG1 monoclonal antibody that specifically targets human TNF-alpha, MW: 144.19 KD. |
| M6104 | Ipilimumab | Ipilimumab (MDX-010, BMS-734016) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor. MW : 148 kD. |
| M6103 | Cetuximab | Cetuximab is a chimeric IgG1 monoclonal antibody to EGFR that inhibits the interaction of EGFR with its ligand. For use in cellular assays, human IgG antibody can be used as an isotype control. (For human and non-humanized mice). |
| M6102 | Pembrolizumab | Pembrolizumab (pembrolizumab) is a humanized anti-PD-1 monoclonal antibody that blocks the interaction between PD-1 and its ligands PD-L1 and PD-L2. It has immune checkpoint inhibitory activity and antitumor activity. MW: 146.286 KD.(Pembrolizumab does not recognize murine PD-1 protein, humanized mice or mice expressing human PD-1 gene are required). |
| M3849 | Aflibercept | Aflibercept is a vascular epidermal growth factor (VEGF-A and PlGF) receptor inhibitor that inhibits the growth of neovascularization. It can be used to study a variety of diseases caused by ocular neovascularization. |
| M3847 | Alemtuzumab | Alemtuzumab is a recombinant DNA-derived humanized IgG1 kappa monoclonal antibody that is directed against the 21-28 kDa cell surface glycoprotein CD52. Alemtuzumab does not cross-react with mouse CD52, making in vivo studies in wild-type mice unfeasible. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
